AcelRx Pharmaceuticals, Inc. (ACRX) Receives Consensus Recommendation of “Hold” from Analysts

Shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) have been assigned a consensus recommendation of “Hold” from the nine ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $5.00.

Several equities research analysts have recently commented on the stock. ValuEngine downgraded shares of AcelRx Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, October 12th. Jefferies Group downgraded shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 13th. Royal Bank Of Canada decreased their target price on shares of AcelRx Pharmaceuticals from $6.00 to $5.00 and set an “outperform” rating for the company in a research report on Friday, October 13th. Roth Capital set a $8.00 target price on shares of AcelRx Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, October 12th. Finally, HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of AcelRx Pharmaceuticals in a research report on Friday, October 27th.

AcelRx Pharmaceuticals (NASDAQ:ACRX) traded down $0.10 during trading hours on Thursday, hitting $2.15. 238,035 shares of the stock traded hands, compared to its average volume of 980,700. The company has a quick ratio of 4.71, a current ratio of 4.78 and a debt-to-equity ratio of -0.43. AcelRx Pharmaceuticals has a one year low of $1.55 and a one year high of $5.75.

In related news, Director Mark G. Edwards bought 30,000 shares of the company’s stock in a transaction on Tuesday, November 14th. The shares were purchased at an average cost of $1.90 per share, for a total transaction of $57,000.00. Following the completion of the purchase, the director now directly owns 150,000 shares in the company, valued at $285,000. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Lawrence G. Hamel sold 10,161 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $5.29, for a total transaction of $53,751.69. Following the completion of the transaction, the insider now owns 16,379 shares in the company, valued at $86,644.91. The disclosure for this sale can be found here. Insiders acquired a total of 42,000 shares of company stock valued at $89,380 over the last ninety days. 28.10% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Perennial Advisors LLC purchased a new position in AcelRx Pharmaceuticals in the third quarter valued at about $138,000. Virtu KCG Holdings LLC boosted its stake in AcelRx Pharmaceuticals by 600.9% in the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock valued at $255,000 after acquiring an additional 101,742 shares during the last quarter. LMR Partners LLP purchased a new position in AcelRx Pharmaceuticals in the second quarter valued at about $319,000. Geller Family Office Services LLC purchased a new position in AcelRx Pharmaceuticals in the third quarter valued at about $460,000. Finally, Goldman Sachs Group Inc. purchased a new position in AcelRx Pharmaceuticals in the second quarter valued at about $530,000. Hedge funds and other institutional investors own 13.94% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was published by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.com-unik.info/2017/12/07/acelrx-pharmaceuticals-inc-acrx-receives-consensus-recommendation-of-hold-from-analysts.html.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

What are top analysts saying about AcelRx Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AcelRx Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit